Hala Borno, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address550 16th. Street
San Francisco CA 94158
Phone415-476-1528
ORCID ORCID Icon0000-0002-4357-975 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    UCSFDiversity, Equity, and Inclusion Champion Training
    UCSFFellowship Hematology/Oncology
    UCSFResidency Internal Medicine
    UNC Chapel HillDoctor of MedicineSchool of Medicine
    UNC Chapel HillBachelor of ScienceBiochemistry
    Collapse Awards and Honors
    NIA2017  - 2019T32-AG000212
    Clinical Innovation Center UCSF2017  - 2018Inside Out Accelerator
    UCSF RAP2018  - 2019Integrative Pilot Award
    Prostate Cancer Foundation2018  - 2021Young Investigator Award

    Collapse Overview 
    Collapse Overview
    Dr. Hala Borno is faculty at UCSF and an Assistant Professor in the Department of Medicine and Division of Hematology/Oncology and co-Medical Director of the Genitourinary Medical Oncology Clinic at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) at the University of California San Francisco (UCSF). Dr. Borno is a medical oncologist with clinical expertise in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. At HDFCCC, Dr. Borno serves on the executive leadership committee for the Prostate Cancer Program and the Liaison to the Office of Community Engagement. She is also a member of the American Society of Clinical Oncology Social Determinants of Health working group, and GU committee for NRG oncology. She serves as the Vice Chair of the Health Disparities Committee for Alliance for Clinical Trials in Oncology.

    Dr. Borno's research program consists of prostate cancer therapeutic development and cancer disparities. She serves as medical oncology co-chair for phase III clinical trials and is the principal investigator for clinical trials conducted at HDFCCC in advanced prostate cancer. Dr. Borno has an extensive research program on the promotion of equity in cancer precision medicine.

    She has developed novel recruitment technologies that are clinician and patient facing to promote diversity and inclusion of racial/ethnic minorities in clinical trials. Dr. Borno used human-centered design to develop Trial LibraryTM, a patient facing clinical trial matching tool. Dr. Borno's research has been featured in peer-reviewed journals such JAMA Oncology, Cancer, and Nature. Her work has been covered by national news outlets such as NPR, Washington Post, CBS News, Bloomberg News, and STAT News.

    Dr. Borno graduated with honors in biochemistry and received her medical degree from the University of North Carolina at Chapel Hill where she was a Medical Alumni Loyalty Fund Scholar. She completed her internal medicine residency and medical oncology fellowship training at UCSF. She served as chief oncology fellow at UCSF and was a National Institute on Aging T32 research fellow in the Division of Geriatrics.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Featured Videos
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis. Journal of Cancer Policy. 2021 Dec 1; 30:100305. Borno BH, Lin LT, Zhang ZS, Skafel SA, Lalanne LA, Dornsife DD, Johnson JR, Spicer SD, Small SE, Rhoads RK. .
      View in: Publisher Site   Mentions:
    2. Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST? NPJ Breast Cancer. 2021 Oct 25; 7(1):139. Abel MK, Melisko ME, Rugo HS, Chien AJ, Diaz I, Levine JK, Griffin A, McGuire J, Esserman LJ, Borno HT, Mukhtar RA. PMID: 34697300; PMCID: PMC8547221.
      View in: PubMed   Mentions:
    3. The Distance Between Us: the COVID-19 Pandemic's Effects on Burnout Among Resident Physicians. Med Sci Educ. 2021 Oct 15; 1-5. Natsuhara KH, Borno HT. PMID: 34692226; PMCID: PMC8519327.
      View in: PubMed   Mentions:
    4. Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancer. Cancer Med. 2021 Oct 12. Kenfield SA, Van Blarigan EL, Panchal N, Bang A, Zhang L, Graff RE, Chen YH, Ryan CJ, Luke A, Newton RU, Tenggara I, Schultz B, Wang E, Lavaki E, Zuniga K, Pinto N, Borno H, Aggarwal R, Friedlander T, Koshkin VS, Harzstark A, Small E, Chan JM. PMID: 34636156.
      View in: PubMed   Mentions:    Fields:    
    5. Predictors of high financial distress in a national, multiethnic sample of patients with cancer. Journal of Clinical Oncology. 2021 Oct 1; 39(28_suppl):149-149. Ragavan RM, Cunningham CR, Incudine IA, Borno BH, Stivers ST. .
      View in: Publisher Site   Mentions:
    6. Evaluating changes in “good safety monitoring” for cancer clinical trial participants during the COVID-19 pandemic. Journal of Clinical Oncology. 2021 Oct 1; 39(28_suppl):217-217. Ragavan RM, LaLanne LA, Skafel SA, Hong HJ, Odisho OA, Yousefi YS, Small SE, Borno BH. .
      View in: Publisher Site   Mentions:
    7. 1571P COVID-19 positivity rates in patients with an active cancer diagnosis in the University of California Cancer Consortium. Annals of Oncology. 2021 Sep 21; 32:s1135. Hong HJ, Borno BH, Harismendy HO, Yousefi YS, Cinar CP, Rugo RH, Kim KM, Koshkin KV, Bailey BA, McKay MR, Small SE. .
      View in: Publisher Site   Mentions:
    8. Broad inclusion leads to maximal value – examining travel costs associated with clinical trial participation. . 2021 Aug 26. Borno BH, Zhang ZS, Nieves NE, Dornsife DD, Johnson JR, Spicer SD, Lin LT. .
      View in: Publisher Site   Mentions:
    9. Implementation of a medical oncology fellow-initiated financial toxicity screening program in outpatient medical oncology clinics. . 2021 Aug 25. Borno BH, Legaspi LN, Brondfield BS, Philip PE, Cinar CP, Zhang ZL. .
      View in: Publisher Site   Mentions:
    10. Prostate cancer patients' self-reported participation in research: an examination of racial/ethnic disparities. Cancer Causes Control. 2021 Oct; 32(10):1161-1172. Palmer NR, Borno HT, Gregorich SE, Livaudais-Toman J, Kaplan CP. PMID: 34189651.
      View in: PubMed   Mentions:    Fields:    
    11. Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):1092-1092. Abel AM, Melisko MM, Rugo RH, Chien CA, Diaz DI, Levine LJ, Griffin GA, McGuire MJ, Esserman EL, Borno BH, Mukhtar MR. .
      View in: Publisher Site   Mentions:
    12. Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423). Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):e16510-e16510. Natesan ND, Zhang ZL, Oh OD, Porten PS, Meng MM, Pruthi PR, Cooperberg CM, Carroll CP, Chou CJ, Borno BH, Bose BR, Desai DA, Kwon KD, Wong WA, Feng FF, Aggarwal AR, Small SE, Fong FL, Friedlander FT, Koshkin KV. .
      View in: Publisher Site   Mentions:
    13. Patterns in cancer management changes for patients with COVID-19 in northern California. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):1535-1535. Glover GM, Wu WJ, Kwon KD, Zhang ZS, Henry HS, Wood WD, Rubin RD, Borno BH, Small SE, Schapira SL, Koshkin KV, Shah SS. .
      View in: Publisher Site   Mentions:
    14. Immunogenic priming with 177 Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):5053-5053. Aggarwal AR, Luch Sam LS, Koshkin KV, Small SE, Feng FF, de Kouchkovsky dI, Kwon KD, Friedlander FT, Borno BH, Bose BR, Chou CJ, Desai DA, Rodvelt RT, Aslam AM, Rastogi RM, Fong FL, Hope HT. .
      View in: Publisher Site   Mentions:
    15. Rate of skeletal-related events (SREs) for abiraterone acetate (AA) versus enzalutamide (ENZ) in prostate cancer: A population-based study using the SEER-Medicare database. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):e17038-e17038. Kwon KD, Paciorek PA, Zhang ZL, Borno BH, Desai DA, Bose BR, Chou CJ, Fong FL, Friedlander FT, Huang HF, Koshkin KV, Small SE, Aggarwal AR. .
      View in: Publisher Site   Mentions:
    16. Redefining Attribution From Patient to Health System-How the Notion of "Mistrust" Places Blame on Black Patients. JAMA Oncol. 2021 May 01; 7(5):780. Borno HT, Andemeskel G, Palmer NR. PMID: 33662096.
      View in: PubMed   Mentions:    Fields:    
    17. Loneliness and symptom burden in oncology patients during the COVID-19 pandemic. Cancer. 2021 09 01; 127(17):3246-3253. Miaskowski C, Paul SM, Snowberg K, Abbott M, Borno HT, Chang SM, Chen LM, Cohen B, Cooper BA, Hammer MJ, Kenfield SA, Kober KM, Laffan A, Levine JD, Pozzar R, Rhoads K, Tsai KK, Van Blarigan EL, Van Loon K. PMID: 33905528.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    18. Evaluating predictors of renal injury with sorafenib in hepatocellular carcinoma: A multi-ethnic cohort study. Journal of Onco-Nephrology. 2021 Apr 19; 239936932110092. Natsuhara NK, Zhang ZL, Carlos CC, Borno BH. .
      View in: Publisher Site   Mentions:
    19. Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. Cancer. 2021 Jun 15; 127(12):1965-1973. Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS. PMID: 33690902.
      View in: PubMed   Mentions:    Fields:    
    20. Examining reporting and representation of patients with cancer in COVID-19 clinical trials. Cancer Rep (Hoboken). 2021 08; 4(4):e1355. Rabow M, Wang C, Zhang S, Tahir PM, Small EJ, Borno HT. PMID: 33621447.
      View in: PubMed   Mentions: Translation:Humans
    21. Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):66-66. Tong TB, Borno BH, Alagala AF, Gordon GK, Small SE, Lin LA, Blanco BA, Dhawan DM. .
      View in: Publisher Site   Mentions:
    22. INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):tps179-tps179. Chen CR, Karrison KT, Lawton LC, Hall HW, Borno BH, Rosu RM, Jani JA, Schuster SD, Seider SM, Efstathiou EJ, Posadas PE, Nguyen NP, Feng FF. .
      View in: Publisher Site   Mentions:
    23. Androgen deprivation therapy and risk of SARS-CoV-2 infection in men with prostate cancer: A University of California (UC) Health System registry study. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):37-37. Kwon KD, Vashisht VR, Borno BH, Aggarwal AR, Small SE, Butte BA, Huang HF. .
      View in: Publisher Site   Mentions:
    24. Implementation of clinician-facing prostate cancer therapeutic clinical trial decision tool at a comprehensive cancer center. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):19-19. Borno BH, Li LP, Zhang ZS, Idossa ID, Desai DA, Rodvelt RT, Bose BR, Koshkin KV, Chou CJ, Friedlander FT, Huang HF, Small SE, Aggarwal AR. .
      View in: Publisher Site   Mentions:
    25. Assessing the impact of the COVID-19 pandemic on patients with genitourinary malignancies. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):38-38. Borno BH, Zhang ZS, Gomez GS, Kaplan KC, Miaskowski MC, Hong HJ, Idossa ID, Bailey BA, Small SE. .
      View in: Publisher Site   Mentions:
    26. Cost-Effectiveness of Immunotherapy Treatments for Renal Cell Carcinoma: A Systematic Review. Kidney Cancer. 2021 Feb 12; 1-16. Philip PE, Zhang ZS, Tahir TP, Kim KD, Wright WF, Bell BA, Borno BH. .
      View in: Publisher Site   Mentions:
    27. Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry. Ann Oncol. 2021 05; 32(5):678-679. Kwon DH, Vashisht R, Borno HT, Aggarwal RR, Small EJ, Butte AJ, Huang FW. PMID: 33571636.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    28. Integrating Financial Toxicity Assessment in Cancer Treatment: Implications for Medical Oncology Training. Journal of Health Science Research. 2021 Jan 29; 30-38. Philip PE, Legaspi LN, Borno BH. .
      View in: Publisher Site   Mentions:
    29. Leveraging Social Media as a Thermometer to Gauge Patient and Caregiver Concerns: COVID-19 and Prostate Cancer. Eur Urol Open Sci. 2021 Mar; 25:1-4. Loeb S, Mihalcea R, Perez-Rosas V, Xu A, Taylor J, Byrne N, Walter D, Ness M, Robbins R, Zhang S, Killeen T, Natesan D, Borno HT. PMID: 34337497.
      View in: PubMed   Mentions:
    30. Integration of electronic pathology reporting with clinical trial matching for advanced prostate cancer. Urol Oncol. 2021 08; 39(8):494.e7-494.e14. Borno HT, Duffy C, Zhang S, Canchola AJ, Loya Z, Golden T, Oh DL, Odisho AY, Gomez S. PMID: 33419644.
      View in: PubMed   Mentions:    Fields:    
    31. Policy and Health: Leveraging a Social Determinants of Health Framework to Alleviate the Impact of the COVID-19 Pandemic on Patients With Cancer. JCO Oncol Pract. 2021 03; 17(3):121-124. Borno HT, Idossa D, Gomez SL. PMID: 33270521.
      View in: PubMed   Mentions: Translation:HumansPHPublic Health
    32. Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer. Cancer Med. 2021 01; 10(1):62-69. Borno HT, Kuo Lin T, Odisho AY, Desai A, Koshkin V, Werner K, Legaspi N, Bucknor M, Bell A, Zhang S, Hope TA. PMID: 33247633.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    33. Disparities in precision medicine-Examining germline genetic counseling and testing patterns among men with prostate cancer. Urol Oncol. 2021 04; 39(4):233.e9-233.e14. Borno HT, Odisho AY, Gunn CM, Pankowska M, Rider JR. PMID: 33158741.
      View in: PubMed   Mentions: 1     Fields:    
    34. Utilization of a multisite financial reimbursement program to promote racial/ethnic diversity and inclusion in therapeutic cancer clinical trials: The iMPACT Study. Journal of Clinical Oncology. 2020 Oct 10; 38(29_suppl):85-85. Borno BH, Zhang ZS, Nieves NE, Dornsife DD, Johnson JR, Spicer SD. .
      View in: Publisher Site   Mentions:
    35. Disparities in PET Imaging for Prostate Cancer at a Tertiary Academic Medical Center. J Nucl Med. 2021 05 10; 62(5):695-699. Bucknor MD, Lichtensztajn DY, Lin TK, Borno HT, Gomez SL, Hope TA. PMID: 32978283.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. Stress and Symptom Burden in Oncology Patients During the COVID-19 Pandemic. J Pain Symptom Manage. 2020 Nov; 60(5):e25-e34. Miaskowski C, Paul SM, Snowberg K, Abbott M, Borno H, Chang S, Chen LM, Cohen B, Hammer MJ, Kenfield SA, Kober KM, Levine JD, Pozzar R, Rhoads KF, Van Blarigan EL, Van Loon K. PMID: 32889039.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    37. Oncology patients' perceptions of and experiences with COVID-19. Support Care Cancer. 2021 Apr; 29(4):1941-1950. Miaskowski C, Paul SM, Snowberg K, Abbott M, Borno H, Chang S, Chen LM, Cohen B, Cooper BA, Hammer MJ, Kenfield SA, Laffan A, Levine JD, Pozzar R, Tsai KK, Van Blarigan EL, Van Loon K. PMID: 32809060.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    38. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry. Urol Oncol. 2020 10; 38(10):793.e1-793.e11. Borno HT, Cowan JE, Zhao S, Broering JM, Carroll PR, Ryan CJ. PMID: 32782182.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. COVID-19 disparities: An urgent call for race reporting and representation in clinical research. Contemp Clin Trials Commun. 2020 Sep; 19:100630. Borno HT, Zhang S, Gomez S. PMID: 32789282.
      View in: PubMed   Mentions: 10  
    40. Determining the impact of Medicaid expansion on cancer burden. Cancer. 2020 09 15; 126(18):4114-4117. Borno HT, Lin TK, Batniji RS. PMID: 32627191.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. The Ethics of Delivering Precision Medicine-Pretest Counseling and Somatic Genomic Testing. JAMA Oncol. 2020 06 01; 6(6):815-816. Borno HT, Rider JR, Gunn CM. PMID: 32163096.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    42. Testicular cancer in Hispanics: incidence of subtypes over time according to neighborhood sociodemographic factors in California. Cancer Causes Control. 2020 Aug; 31(8):713-721. DeRouen MC, McKinley M, Shah SA, Borno HT, Aoki R, Lichtensztajn DY, Leppert JT, Brooks JD, Chung BI, Gomez SL, Cheng I. PMID: 32440828.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    43. Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):1590-1590. Tong TB, Borno BH, Small SE, Alagala AF, Blanco BA, Dhawan DM. .
      View in: Publisher Site   Mentions:
    44. Sipuleucel-T (sip-T) and oral androgen axis inhibitors in black men being treated for metastatic castration-resistance prostate cancer (mCRPC): Observations from the Medicare Fee for Service (FFS) population. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):e17589-e17589. Borno BH, Moses MK, Monk MP, Fitch FK, Harmon HM, Flanders FS, McKay MR. .
      View in: Publisher Site   Mentions:
    45. Racial disparities and online health information: YouTube and prostate cancer clinical trials. BJU Int. 2020 07; 126(1):11-13. Borno HT, Zhang S, Bakke B, Bell A, Zuniga KB, Li P, Chao K, Sabol A, Killeen T, Hong H, Walter D, Loeb S. PMID: 32275800.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    46. Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research? Contemp Clin Trials. 2020 05; 92:105997. Borno HT, Small EJ. PMID: 32272172.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsPHPublic Health
    47. The limitations of today's clinical guidance: Atypical femoral fracture and long-term bone-modifying agents in the oncology setting. J Oncol Pharm Pract. 2020 Jul; 26(5):1180-1189. Cheung E, Borno HT. PMID: 32122232.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    48. The Problem of Underrepresentation: Black Participants in Lifestyle Trials Among Patients with Prostate Cancer. J Racial Ethn Health Disparities. 2020 10; 7(5):996-1002. Zuniga KB, Borno H, Chan JM, Van Blarigan EL, Friedlander TW, Wang S, Zhang L, Kenfield SA. PMID: 32078741.
      View in: PubMed   Mentions:    Fields:    
    49. Efficacy of immune checkpoint inhibitors (ICIs) in rare histological variants of bladder cancer. Journal of Clinical Oncology. 2020 Feb 20; 38(6_suppl):502-502. Philip PE, Wright WF, Kim KD, Kwon KD, Ho HH, Ho HS, Cheung CE, Chan CE, Porten PS, Wong WA, Borno BH, Desai DA, Chou CJ, Oh OD, Aggarwal AR, Fong FL, Small SE, Friedlander FT, Koshkin KV. .
      View in: Publisher Site   Mentions:
    50. Disparities in receipt of molecular imaging in biochemical recurrent prostate cancer. Journal of Clinical Oncology. 2020 Feb 20; 38(6_suppl):297-297. Borno BH, Lin LT, Odisho OA, Desai DA, Koshkin KV, Werner WK, Legaspi LN, Bell BA, Hope HT. .
      View in: Publisher Site   Mentions:
    51. REACT: A feasibility study to test the integration of a cancer registry early case ascertainment process via electronic pathology reporting with an online clinical trial matching tool. Journal of Clinical Oncology. 2020 Feb 20; 38(6_suppl):207-207. Borno BH, Duffy DC, Zhang ZS, Loya LZ, Golden GT, Oh OD, Odisho OA, Gomez GS. .
      View in: Publisher Site   Mentions:
    52. Treatment outcomes in metastatic prostate cancer patients with DNA damage repair mutations. Journal of Clinical Oncology. 2020 Feb 20; 38(6_suppl):187-187. Kwon KD, Wright WF, Zhang ZL, Chou CJ, Borno BH, Desai DA, Oh OD, Pollock PY, Bose BR, Huang HF, Hope HT, Friedlander FT, Fong FL, Feng FF, Small SE, Aggarwal AR, Koshkin KV. .
      View in: Publisher Site   Mentions:
    53. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urol Oncol. 2020 03; 38(3):83-93. Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, Mucci L, Parsons JK, Saad F, Soule H, Morgans A, Ryan CJ. PMID: 31734020.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    54. A step towards equitable clinical trial recruitment: a protocol for the development and preliminary testing of an online prostate cancer health information and clinical trial matching tool. Pilot Feasibility Stud. 2019; 5:123. Borno HT, Bakke BM, Kaplan C, Hebig-Prophet A, Chao J, Kim YJ, Yeager J, Cinar P, Small E, Boscardin C, Gonzales R. PMID: 31720002.
      View in: PubMed   Mentions: 1  
    55. How current reporting practices may mask differences: A call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trials. Contemp Clin Trials Commun. 2019 Dec; 16:100476. Borno HT, Small EJ, Zhang L, DeRouen MC, Griffin A, McGuire J, Ryan CJ, Hiatt RA, Kaplan CP. PMID: 31872154.
      View in: PubMed   Mentions: 1  
    56. Ethnic disparities among men with prostate cancer undergoing germline testing. Urol Oncol. 2020 03; 38(3):80.e1-80.e7. Kwon DH, Borno HT, Cheng HH, Zhou AY, Small EJ. PMID: 31630993.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    57. An electronic registry to improve adherence to active surveillance monitoring among men with prostate cancer at a safety-net hospital: protocol for a pilot study. Pilot Feasibility Stud. 2019; 5:101. Cedars B, Lisker S, Borno HT, Kamal P, Breyer B, Sarkar U. PMID: 31428442.
      View in: PubMed   Mentions:
    58. Tailoring survivorship to diverse populations with genitourinary malignancies. Urol Oncol. 2020 03; 38(3):118-120. Borno HT, Dixit N. PMID: 31307880.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    59. Food insecurity screening: A missing piece in cancer management. Cancer. 2019 Oct 15; 125(20):3494-3501. Patel KG, Borno HT, Seligman HK. PMID: 31287159.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    60. All Men Are Created Equal: Addressing Disparities in Prostate Cancer Care. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:302-308. Borno H, George DJ, Schnipper LE, Cavalli F, Cerny T, Gillessen S. PMID: 31099647.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    61. Germline Genetic Testing in Advanced Prostate Cancer - Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clinical Genitourinary Cancer. 2019. . View Publication.
    62. Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clin Genitourin Cancer. 2019 08; 17(4):275-282.e1. Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan CJ, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN, PCCTC Germline Genetics Working Group . PMID: 31171481.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    63. An electronic registry to improve adherence to active surveillance monitoring among men with prostate cancer at a safety-net hospital: protocol for a pilot study. Pilot and Feasibility Studies. 2019; 5:101. .
    64. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer. Cancer. 2019 02 01; 125(3):453-462. Borno HT, Lichtensztajn DY, Gomez SL, Palmer NR, Ryan CJ. PMID: 30444526.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    65. Apalutamide and its use in the treatment of prostate cancer. Future Oncol. 2019 Feb; 15(6):591-599. Borno HT, Small EJ. PMID: 30426794.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    66. Journal of Clinical Oncology. Implementation of a fellow-initiated financial toxicity screening tool in medical oncology clinics. 2018; 30_suppl(36):64-64. View Publication.
    67. A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy. Contemp Clin Trials Commun. 2018 Dec; 12:60-67. Kaplan CP, Siegel A, Leykin Y, Palmer NR, Borno H, Bielenberg J, Livaudais-Toman J, Ryan C, Small EJ. PMID: 30272035.
      View in: PubMed   Mentions: 3  
    68. Being Present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers. PLoS One. 2018; 13(7):e0199423. Atreya CE, Kubo A, Borno HT, Rosenthal B, Campanella M, Rettger JP, Joseph G, Allen IE, Venook AP, Altschuler A, Dhruva A. PMID: 30036361.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    69. At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials. Oncologist. 2018 10; 23(10):1242-1249. Borno HT, Zhang L, Siegel A, Chang E, Ryan CJ. PMID: 29700209.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    70. Journal of Clinical Oncology. Minority Equity and Recruitment Into Trials program: Self-assessment of disease-specific cancer clinical trial recruitment patterns at a comprehensive cancer center. 2018; 36(6_suppl ):267-267. . View Publication.
    71. Minority Equity and Recruitment Into Trials program: Self-assessment of disease-specific cancer clinical trial recruitment patterns at a comprehensive cancer center. Journal of Clinical Oncology. 2018 Feb 20; 36(6_suppl):267-267. Borno BH, McGuire MJ, Griffin GA, Ryan RC, Kaplan KC, Small SE. .
      View in: Publisher Site   Mentions:
    72. CaPSURE update: Examining primary treatment and survival among men with prostate cancer and bony metastatic disease. Journal of Clinical Oncology. 2018 Feb 20; 36(6_suppl):275-275. Borno BH, Cowan CJ, Zhao ZS, Carroll CP, Ryan RC. .
      View in: Publisher Site   Mentions:
    73. Blood and conflict: managing bleeding disorders in Gaza. East Mediterr Health J. 2018 Jan 02; 23(11):786-787. Borno H. PMID: 29319151.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    74. An unusual manifestation of diabetic ketoacidosis and acute colonic pseudo-obstruction. JRSM Open. 2017 Jun; 8(6):2054270417698632. Natalini J, Borno H, Jin L, Jensen T. PMID: 28620506.
      View in: PubMed   Mentions: 1  
    75. Improving documentation of surrogate decision makers in medical oncology clinic. Journal of Clinical Oncology. 2017 Mar 10; 35(8_suppl):63-63. Wong WM, Borno BH, Mahajan MR, Bischoff BK, Calton CB, Bergsland BE, Kim KW, Aggarwal AR, Tsai TK, Cinar CP. .
      View in: Publisher Site   Mentions:
    76. The problem of representativeness of clinical trial participants: understanding the role of hidden costs. J Health Serv Res Policy. 2016 07; 21(3):145-6. Borno H, Siegel A, Ryan C. PMID: 26888478.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    77. Incidence of cleft lip and palate in the palestinian territories: a retrospective study from the Makassed Hospital neonatal unit. Cleft Palate Craniofac J. 2014 Jul; 51(4):472-5. Borno HT, Hussein EA, Dudin A, van Aalst JA. PMID: 23551076.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    78. Cleft Lip and Palate Diagnosis and Management. Birthing and Building Nascent Cleft Teams in Developing Countries. 2012; 871-877. Hussein E, Borno HT, van Aalst JA.
    Hala's Networks
    Concepts (153)
    Derived automatically from this person's publications.
    _
    Co-Authors (72)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _